Chun Helen M, Lodiongo Dennis K, Milligan Kyle, Lesuk Grace J, Patel Divya, Shiraishi Ray W, Martin Diana, Simon Ashley K, Dirlikov Emilio, Patel Hetal K, Ellenberger Dennis, Worku Habtamu A, Duong Yen T, Ekong Robert O, Katoro Joel S, Hussen Shambel A, Lokore Michael L, Wani Gregory, Bunga Sudhir
Division of Global HIV & Tuberculosis, Global Health Center, Centers for Disease Control and Prevention, Atlanta, USA.
Division of Global HIV & Tuberculosis, Global Health Center, Centers for Disease Control and Prevention, Juba, South Sudan.
IJID Reg. 2024 Aug 8;12:100421. doi: 10.1016/j.ijregi.2024.100421. eCollection 2024 Sep.
The burden of SARS-CoV-2 infection in people living with HIV (PLHIV) in South Sudan is unknown.
We conducted a cross-sectional seroprevalence survey of SARS-CoV-2 immunoglobulin (Ig) G antibodies and other diseases of public health importance (strongyloidiasis, toxoplasmosis) in PLHIV in South Sudan during April 1, 2020-April 30, 2022. We used a multiplex SARS-CoV-2 immunoassay to detect IgG antibodies targeting the SARS-CoV-2 spike, receptor binding domain, and nucelocapsid (N) proteins, and antigens for other pathogens ().
Among 3518 samples tested, seroprevalence of IgG antibodies to SARS-CoV-2 spike protein and receptor binding domain 591 and nucleocapsid ranged from 1.4% (95% confidence interval [CI]: 0.9-2.1%) in April-June 2020 to 53.3% (95% CI: 49.5-57.1%) in January-March 2022. The prevalence of IgG ranged between 27.3% (95% CI: 23.4-31.5%) in October-December 2021 and 47.2% (95% CI: 37.8-56.8%) in July-September 2021, and, for IgG, prevalence ranged from 15.5% (95% CI: 13.3-17.9%) in April-June 2020 to 36.2% (95% CI: 27.4-46.2%) July-September 2021.
By early 2022, PLHIV in South Sudan had high rates of SARS-CoV-2 seropositivity. Surveillance of diseases of global health concern in PLHIV is crucial to estimate population-level exposure and inform public health responses.
南苏丹艾滋病毒感染者（PLHIV）中新型冠状病毒2（SARS-CoV-2）感染的负担尚不清楚。
在2020年4月1日至2022年4月30日期间，我们对南苏丹的艾滋病毒感染者进行了一项关于SARS-CoV-2免疫球蛋白（Ig）G抗体以及其他具有公共卫生重要性的疾病（类圆线虫病、弓形虫病）的横断面血清流行率调查。我们使用一种多重SARS-CoV-2免疫测定法来检测针对SARS-CoV-2刺突蛋白、受体结合结构域和核衣壳（N）蛋白的IgG抗体，以及针对其他病原体的抗原。
在检测的3518份样本中，2020年4月至6月期间，针对SARS-CoV-2刺突蛋白、受体结合结构域591和核衣壳的IgG抗体血清流行率为1.4%（95%置信区间[CI]：0.9-2.1%），到2022年1月至3月时为53.3%（95%CI：49.5-57.1%）。2021年10月至12月期间IgG的流行率在27.3%（95%CI：23.4-31.5%）之间，2021年7月至9月期间为47.2%（95%CI：37.8-56.8%）；对于IgG，2020年4月至6月期间的流行率为15.5%（95%CI：13.3-17.9%），到2021年7月至9月时为36.2%（95%CI：27.4-46.2%）。
到2022年初，南苏丹的艾滋病毒感染者中SARS-CoV-2血清阳性率很高。对艾滋病毒感染者中全球关注疾病的监测对于估计人群层面的暴露情况并为公共卫生应对提供信息至关重要。
